Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796186 | 0.77 | APLNR (0.44) | POLBAPLNRALDH1A1KDM4EHTT | |
| SCHEMBL13168247 | 0.75 | ALDH1A1 (0.60) | POLBAPLNRALDH1A1KDM4ETSHR | |
| SCHEMBL24562736 | 0.75 | ALDH1A1 (0.45) | POLBAPLNRALDH1A1KDM4ETSHR | |
| SCHEMBL7602457 | 0.73 | SLC6A4 (0.65) | APLNRALDH1A1KDM4ETSHRMEN1 | |
| SCHEMBL7338769 | 0.72 | APLNR (0.58) | POLBAPLNRALDH1A1KDM4ETSHR | |
| SCHEMBL11477519 | 0.70 | APLNR (0.66) | APLNRALDH1A1CA2CA12CA1 | |
| SCHEMBL23378290 | 0.70 | APLNR (0.45) | POLBAPLNRALDH1A1KDM4ETSHR | |
| SCHEMBL17919505 | 0.70 | ALDH1A1 (0.54) | POLBAPLNRALDH1A1KDM4ETSHR | |
| SCHEMBL5780504 | 0.70 | MAPT (0.43) | ALDH1A1KDM4EMEN1KMT2ASLC6A4 | |
| SCHEMBL12522848 | 0.69 | APLNR (0.54) | POLBAPLNRALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240492-B1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-07-07 | — | — | US | disclosed |
| US-7964739-B2 | Through a stilbene derivative, to a pyrrolidine intermediate, followed by cyclization; asenapine is an antipsychotic agent; industrial scale | N.V. ORGANON (NL) | 2011-06-21 | — | — | US | disclosed |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | POLB 1214/4885APLNR 651/4885ALDH1A1 600/4885 |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | POLB 1214/4885APLNR 651/4885ALDH1A1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.